Cumberland Pharmaceuticals (CPIX) Set to Post Quarterly Earnings on Tuesday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is anticipated to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $8.50 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Trading Down 48.8%

Shares of CPIX opened at $4.35 on Tuesday. Cumberland Pharmaceuticals has a 12 month low of $1.85 and a 12 month high of $9.28. The firm has a fifty day simple moving average of $7.36 and a 200 day simple moving average of $5.53. The stock has a market capitalization of $65.16 million, a price-to-earnings ratio of -6.13 and a beta of 0.06.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company headquartered in Nashville, Tennessee. The company develops, acquires and commercializes prescription medicines, with a focus on products that address unmet needs in critical care, gastroenterology, pain management and other specialty areas.

Its portfolio has included Caldolor (ibuprofen injection), Acetadote (acetylcysteine injection), Kristalose (lactulose for oral solution), Vaprisol (conivaptan hydrochloride injection) and Omeclamox-Pak, a treatment for certain Helicobacter pylori infections.